
CDR L1 - Contact
CDR L1 - Chothia
CDR L1 - Kabat
CDR L2 - Contact
CDR L2 - Chothia
CDR L2 - Kabat
CDR L3 - Contact
CDR L3 - Chothia
CDR L3 - Kabat
Kabat number
rat.1B2
hu.1B2.L1
hu.1B2.L7

FIG. 1A


CDR H1 - Contact
CDR H1 - Kabat
CDR H2 - Contact
CDR H2 - Kabat
CDR H3 - Contact
CDR H3 - Kabat
Kabat number
rat.1B2
hu.1B2.v1.DFS.H1
hu.1B2.H10
hu.1B2.DFS.H14
hu.1B2.H1.N54D.S51Q
hu.1B2.v2
hu.1B2.v4
hu.1B2.v8
hu.1B2.v9
hu.1B2.v101
hu.1B2.v102
hu.1B2.v103
hu.1B2.v104

FIG. 1B


Light chain variable region
CDR L1 - Contact
CDR L1 - Kabat
CDR L2 - Contact
CDR L2 - Kabat
CDR L3 - Contact
CDR L3 - Kabat
Kabat number
rat.Notch2-3107

FIG. 2A


Heavy chain variable region
CDR H1 - Contact
CDR H1 - Kaba
CDR H2 - Contact
CDR H2 - Kabat
CDR H3 - Contact
CDR H3 - Kabat
Kabat number
rat.Notch2-3107
Q V Q L Q Q S G A E L A K S G S S V K I S C K A S G Y T F S N Y V I H W I K Q T T G
Q A P E W T G Y I I P G S G G T K F N E K F K G K A T L T V D K S S T T A Y M Q L S
S L T P V D T A V Y Y C A R D G A G S F T Y W G Q G T L V T V S S

FIG. 2B

CDR L1 - Contact
CDR L1 - Kabat
CDR L2 - Contact
CDR L2 - Kabat
CDR L3 - Contact
CDR L3 - Kabat
Kabat number
rb.2338
rb.2430
rb.2430.C95dS
rb.2621

FIG. 3A


CDR H1 - Contact
CDR H1 - Kabat
CDR H2 - Contact
CDR H2 - Kabat
CDR H3 - Contact
CDR H3 - Kabat
Kabat number
rb.2338
rb.2430
rb.2621

FIG. 3B


1B2 binning profile
59R5
1B2
rat.3107
rb.2338
rb.2430
rb.2621
50nM
hNotch2
Normalized Response
Time (s)
rb.2338, rb.2430, rb.2621
binning profile
59R5
1B2
rat.3107
rb.2338
rb.2430
rb.2621
50nM
hNotch2
Normalized Response
Time (s)
#blue lines are buffer
59R5 binning profile
1B2
rat.3107
rb.2338
rb.2430
rb.2621
59R5
50nM
hNotch2
Normalized Response
Time (s)

FIG. 4


Jag1-Dependent Notch2 Signaling
Activity [%]
0
-50
-100
-11
-10
-9
-8
-7
-6
Log Concentration [M]
1B02 Chimeric
1B02.v1 N54D
1B02.v101
1B02.v102
1B02.v103
1B02.v104

FIG. 5A


DLL1-Dependent Notch2 Signaling
Activity [%]
0
-50
-100
-11
-10
-9
-8
-7
-6
Log Concentration [M]
1B02 Chimeric
1B02.v1 N54D
1B02.v101
1B02.v102
1B02.v103
1B02.v104

FIG. 5B


Jag1-Dependent Notch2 Signaling
0
-50
-100
Activity [%]
rat 3107
-11
-10
-9
-8
-7
-6
Log Concentration [M]

FIG. 5C


DLL1-Dependent Notch2 Signaling
0
-50
-100
Activity [%]
rat 3107
-11
-10
-9
-8
-7
-6
Log Concentration [M]

FIG. 5D


Jag1-Dependent Notch2 Signaling
Activity [%]
0
20
40
60
80
-11
-10
-9
-8
-7
-6
Log Concentration [M]
rabbit 2621
rabbit 2338
rabbit 2430

FIG. 5E


DLL1-Dependent Notch2 Signaling
Activity [%]
0
-50
-100
-11
-10.5
-10
-9.5
-9
-8.5
-8
-7.5
-7
-6.5
-6
Log Concentration [M]
rabbit 2621
rabbit 2338
rabbit 2430

FIG. 5F



FIG. 6C



FIG. 6B



FIG. 6A





FIG. 6D


CDR L1 - Contact
CDR L1 - Chothia
CDR L1 - Kabat
CDR L2 - Contact
CDR L2 - Chothia
CDR L2 - Kabat
CDR L3 - Contact
CDR L3 - Chothia
CDR L3 - Kabat
Kabat number
rat.3107
hu.3107.L1
hu.3107.L6
hu.3107.L7

FIG. 7A


CDR H1 - Contact
CDR H1 - Kabat
CDR H2 - Contact
CDR H2 - Kabat
CDR H3 - Contact
CDR H3 - Kabat
Kabat number
rat.3107
hu.3107.V1-2.H1
hu.3107.H12
hu.3107.H13
hu.3107.V5-51.H1
hu.3107.H14
hu.3107.H15

FIG. 7B

INTERNATIONAL SEARCH REPORT

WO 2022/016037

International application No
PCT/UPCT/US2021/041935

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K16/28 A61P11/00 A61K39/395
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 2010/005566 A2 (ONCOMED PHARM INC [US]; GURNEY AUSTIN L [US] ET AL.) 14 January 2010 (2010-01-14) paragraphs [0021] - [0024] [0202], figures, in particular figure 1, 15 tables 1, 3, examples, sequences	1-7,17, 19-23, 33-49,51 8-16,18, 24-32, 50,52-67

X Y	WO 2013/173542 A1 (ONCOMED PHARM INC [US]) 21 November 2013 (2013-11-21) paragraphs [0064], [0078] examples, sequences	1-7,17, 19-23, 33-49,51 8-16,18, 24-32, 50,52-67

	-/--	

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
11 October 2021	19/10/2021

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Bernhardt, Wiebke

1

Form PCT/ISA/210 (second sheet) (April 2005)